Gene therapy for the treatment of musculoskeletal diseases.

Christopher H Evans, Steven C. Ghivizzani, James H. Herndon, Paul D. Robbins

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Research into the orthopaedic applications of gene therapy has resulted in progress toward managing chronic and acute genetic and nongenetic disorders. Gene therapy for arthritis, the original focus of research, has progressed to the initiation of several phase I clinical trials. Preliminary findings support the application of gene therapy in the treatment of additional chronic conditions, including osteoporosis and aseptic loosening, as well as musculoskeletal tumors. The most rapid progress is likely to be in tissue repair because it requires neither long-term transgene expression nor closely regulated levels of transgene expression. Moreover, healing probably can be achieved with existing technology. In preclinical studies, genetically modulated stimulation of bone healing has shown impressive results in repairing segmental defects in the long bones and cranium and in improving the success of spinal fusions. An increasing amount of evidence indicates that gene transfer can aid the repair of articular cartilage, menisci, intervertebral disks, ligaments, and tendons. These developments have the potential to transform many areas of musculoskeletal care, leading to treatments that are less invasive, more effective, and less expensive than existing modalities.

Original languageEnglish (US)
Pages (from-to)230-242
Number of pages13
JournalThe Journal of the American Academy of Orthopaedic Surgeons.
Volume13
Issue number4
StatePublished - Jul 2005
Externally publishedYes

Fingerprint

Musculoskeletal Diseases
Genetic Therapy
Transgenes
Bone and Bones
Spinal Fusion
Clinical Trials, Phase I
Inborn Genetic Diseases
Intervertebral Disc
Articular Cartilage
Ligaments
Research
Skull
Tendons
Osteoporosis
Arthritis
Orthopedics
Therapeutics
Technology
Genes
Neoplasms

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine
  • Surgery

Cite this

Gene therapy for the treatment of musculoskeletal diseases. / Evans, Christopher H; Ghivizzani, Steven C.; Herndon, James H.; Robbins, Paul D.

In: The Journal of the American Academy of Orthopaedic Surgeons., Vol. 13, No. 4, 07.2005, p. 230-242.

Research output: Contribution to journalArticle

Evans, Christopher H ; Ghivizzani, Steven C. ; Herndon, James H. ; Robbins, Paul D. / Gene therapy for the treatment of musculoskeletal diseases. In: The Journal of the American Academy of Orthopaedic Surgeons. 2005 ; Vol. 13, No. 4. pp. 230-242.
@article{a3129b362fd54ece83f9b4b6d9718175,
title = "Gene therapy for the treatment of musculoskeletal diseases.",
abstract = "Research into the orthopaedic applications of gene therapy has resulted in progress toward managing chronic and acute genetic and nongenetic disorders. Gene therapy for arthritis, the original focus of research, has progressed to the initiation of several phase I clinical trials. Preliminary findings support the application of gene therapy in the treatment of additional chronic conditions, including osteoporosis and aseptic loosening, as well as musculoskeletal tumors. The most rapid progress is likely to be in tissue repair because it requires neither long-term transgene expression nor closely regulated levels of transgene expression. Moreover, healing probably can be achieved with existing technology. In preclinical studies, genetically modulated stimulation of bone healing has shown impressive results in repairing segmental defects in the long bones and cranium and in improving the success of spinal fusions. An increasing amount of evidence indicates that gene transfer can aid the repair of articular cartilage, menisci, intervertebral disks, ligaments, and tendons. These developments have the potential to transform many areas of musculoskeletal care, leading to treatments that are less invasive, more effective, and less expensive than existing modalities.",
author = "Evans, {Christopher H} and Ghivizzani, {Steven C.} and Herndon, {James H.} and Robbins, {Paul D.}",
year = "2005",
month = "7",
language = "English (US)",
volume = "13",
pages = "230--242",
journal = "Journal of the American Academy of Orthopaedic Surgeons",
issn = "1067-151X",
publisher = "American Association of Orthopaedic Surgeons",
number = "4",

}

TY - JOUR

T1 - Gene therapy for the treatment of musculoskeletal diseases.

AU - Evans, Christopher H

AU - Ghivizzani, Steven C.

AU - Herndon, James H.

AU - Robbins, Paul D.

PY - 2005/7

Y1 - 2005/7

N2 - Research into the orthopaedic applications of gene therapy has resulted in progress toward managing chronic and acute genetic and nongenetic disorders. Gene therapy for arthritis, the original focus of research, has progressed to the initiation of several phase I clinical trials. Preliminary findings support the application of gene therapy in the treatment of additional chronic conditions, including osteoporosis and aseptic loosening, as well as musculoskeletal tumors. The most rapid progress is likely to be in tissue repair because it requires neither long-term transgene expression nor closely regulated levels of transgene expression. Moreover, healing probably can be achieved with existing technology. In preclinical studies, genetically modulated stimulation of bone healing has shown impressive results in repairing segmental defects in the long bones and cranium and in improving the success of spinal fusions. An increasing amount of evidence indicates that gene transfer can aid the repair of articular cartilage, menisci, intervertebral disks, ligaments, and tendons. These developments have the potential to transform many areas of musculoskeletal care, leading to treatments that are less invasive, more effective, and less expensive than existing modalities.

AB - Research into the orthopaedic applications of gene therapy has resulted in progress toward managing chronic and acute genetic and nongenetic disorders. Gene therapy for arthritis, the original focus of research, has progressed to the initiation of several phase I clinical trials. Preliminary findings support the application of gene therapy in the treatment of additional chronic conditions, including osteoporosis and aseptic loosening, as well as musculoskeletal tumors. The most rapid progress is likely to be in tissue repair because it requires neither long-term transgene expression nor closely regulated levels of transgene expression. Moreover, healing probably can be achieved with existing technology. In preclinical studies, genetically modulated stimulation of bone healing has shown impressive results in repairing segmental defects in the long bones and cranium and in improving the success of spinal fusions. An increasing amount of evidence indicates that gene transfer can aid the repair of articular cartilage, menisci, intervertebral disks, ligaments, and tendons. These developments have the potential to transform many areas of musculoskeletal care, leading to treatments that are less invasive, more effective, and less expensive than existing modalities.

UR - http://www.scopus.com/inward/record.url?scp=27544467720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27544467720&partnerID=8YFLogxK

M3 - Article

C2 - 16112980

AN - SCOPUS:27544467720

VL - 13

SP - 230

EP - 242

JO - Journal of the American Academy of Orthopaedic Surgeons

JF - Journal of the American Academy of Orthopaedic Surgeons

SN - 1067-151X

IS - 4

ER -